Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease

Background/aim: F2&alpha;-isoprostane is accepted as an oxidative stress indicator and melatonin shows neuroprotective effects by antioxidative and antiamyloidogenic influences. By measuring these in patients diagnosed with minimal cognitive impairment (MCI) and Alzheimer-type dementia, we intended to demonstrate whether the measurement of these markers contributes to early diagnosis of Alzheimer disease (AD) in the MCI stage or not. Materials and methods: Three groups (n = 63) were created: the AD group, MCI group, and control group. Serum melatonin levels were measured by radioimmunoassay method, and plasma total 8-isoPGF2&alpha; levels were measured by enzyme immunoassay method. Results: Significant differences were observed in the melatonin levels between the MCI group and AD group (P = 0.009), and in 8-isoPGF2&alpha; levels between the AD group and control group (P = 0.022). A negative correlation between mini-mental state examination (MMSE) scores and 8-isoPGF2&alpha; levels (r = -0.459, P < 0.001) and positive correlation between MMSE scores and melatonin levels (r = 0.317, P = 0.011) were found. Conclusion: Although the plasma 8-isoPGF2&alpha; and serum melatonin levels in MCI were not found to be good early diagnostic markers to indicate risk of AD, results were found to support the role of oxidative stress in AD.

Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease

Background/aim: F2&alpha;-isoprostane is accepted as an oxidative stress indicator and melatonin shows neuroprotective effects by antioxidative and antiamyloidogenic influences. By measuring these in patients diagnosed with minimal cognitive impairment (MCI) and Alzheimer-type dementia, we intended to demonstrate whether the measurement of these markers contributes to early diagnosis of Alzheimer disease (AD) in the MCI stage or not. Materials and methods: Three groups (n = 63) were created: the AD group, MCI group, and control group. Serum melatonin levels were measured by radioimmunoassay method, and plasma total 8-isoPGF2&alpha; levels were measured by enzyme immunoassay method. Results: Significant differences were observed in the melatonin levels between the MCI group and AD group (P = 0.009), and in 8-isoPGF2&alpha; levels between the AD group and control group (P = 0.022). A negative correlation between mini-mental state examination (MMSE) scores and 8-isoPGF2&alpha; levels (r = -0.459, P < 0.001) and positive correlation between MMSE scores and melatonin levels (r = 0.317, P = 0.011) were found. Conclusion: Although the plasma 8-isoPGF2&alpha; and serum melatonin levels in MCI were not found to be good early diagnostic markers to indicate risk of AD, results were found to support the role of oxidative stress in AD.

___

Selekler K. Alzheimer hastalığının öncesi: hafif kognitif bozukluk. Hacettepe Tıp Dergisi 2004; 35: 199–206 (in Turkish).

Petersen RC. Mild cognitive impairment: where are we? Alzheimer Dis Assoc Disord 2005; 19: 166–169.

Chertkow H. Mild cognitive impairment. Curr Opin Neurol 2002; 15: 401–407. 4. Cardinalli DP, Vigo DE, Olivar N, Vidal MF, Furio AM, Brusco LI. Therapeutic application of melatonin in mild cognitive impairment. Am J Neurodegener Dis 2012; 1: 280–291.

Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer’s disease. Neurobiol Aging 1997; 18: 85–88.

Montine TJ, Neely MD, Quinn JF, Beal F, Markesbery WR. Lipid peroxidation in aging brain and Alzheimer’s Disease. Free Radic Biol Med 2002; 33: 620–626. 7. Pratico D, Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer’s disease. Am J Med 2000; 109: 577–585.

Smith MA, Rottkamp C, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer’s disease. Biochim Biophys Acta 2000; 1502: 139–144.

ChristenY. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000; 71: 621–629.

Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 827: 65–75.

Praticò D, Lawson JA, Rokach J, FitzGerald GA. The isoprostanes in biology and medicine. Trends Endocrinol Metab 2001; 12: 243–247.

Pratico D, Lawson JA, FitzGerald GA. Cyclooxygenase- dependent formation of the isoprostane, 8-epi PGF2α. J Biol Chem 1995; 270: 9800–9808.

Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 2003; 17: 273–285.

Matuszak Z, Reszka KJ, Chignell CF. Reaction of melatonin and related indoles with hydroxyl radicals: ESR and spin trapping investigations. Free Radic Biol Med 1997; 23: 367–372.

Pappolla MA, Chyan YJ, Poeggeler B. An assessment of the antioxidant and antiamyloidogenic properties of melatonin: implications for Alzheimer’s disease. J Neural Transm 2000; 107: 203–231.

Bettahi I, Pozo D, Osuna C, Reiter RJ, Acuna-Castroviejo D, Guerrero JM. Melatonin reduces nitric oxide synthase activity in rat hypothalamus. J Pineal Res 1996; 20: 205–210.

Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 1999; 84: 323– 327.

Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res 2005; 38: 145–152.

Amuk T, Karadağ F, Oğuzhanoğlu N, Oğuzhanoğlu A. Cornell demansta depresyon ölçeği’nin Türk yaşlı toplumunda geçerlik ve güvenilirliği. Türk Psikiyatri Dergisi 2003; 14: 263–271 (in Turkish).

Reisberg B, Ferris SH, de Leon MJ. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136–1139.

Diker J, Etiler N, Yıldız M, Şeref B. Altmış beş yaş üzerindeki kişilerde bilişsel durumun günlük yaşam aktiviteleri, yaşam kalitesi ve demografik değişkenlerle ilişkisi. Anadolu Psikiyatri Dergisi 2001; 2: 79–86 (in Turkish).

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC, USA: APA; 1994.

Ceyhun B. Demansın psikolojik değerlendirilmesi. Demans Dizisi 1999; 3: 90–103.

Folstein MF, Folstein SF, McHugh PR. Mini Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiat Research 1975; 12: 189–198.

Ertan T, Eker E, Güngen C, Engin F, Yaşar R, Kılıç G, Özel S. The Standardized Mini Mental State Examination for illiterate Turkish elderly population. In: 2nd International Symposium on Neurophysiological and Neuropsychological Assessment of Mental and Behavioral Disorders; 1999.

Petersen RC, Smith GE, Waring SC, Ivnik RC, Tangalos EG, Kökmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303–308.

Montine TJ, Markesbery WR, Morrow JD, Roberts LJ. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer’s disease. Ann Neurol 1998; 44: 410–413.

Pratico D, Lee VMY, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in Alzheimer’s disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998; 12: 1777– 1783.

Pratico D, Clark CM, Lee VMY, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased 8,12-iso-iPF2α-VI in Alzheimer’s disease: correlation of a non-invasive index of lipid peroxidation with disease severity. Ann Neurol 2000; 48: 809–812.

Tuppo EE, Forman LJ, Spur BW, Chan-Ting RE, Chopra A, Cavalieri TA. Sign of lipid peroxidation as measured inthe urine of patients with probable Alzheimer’s disease. Brain Res Bull 2001; 54: 565–568.

Pratico D, Clark CM, Linn F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002; 59: 972–976.

Irizary MC, Yao Y, Hyman BT, Growdon JH, Pratico D. Plasma F2 isoprostane levels in Alzheimer’s and Parkinson’s disease. Neurodegener Dis 2007; 4: 403–405.

Mufson E, Leurgans S. Inability of plasma and urine F2α- isoprostane levels to differentiate mild cognitive impairment from Alzheimer’s disease. Neurodegener Dis 2010; 7: 139–142.

Kuo HC, Yen HC, Huang CC, Hsu WC, Wei HJ, Lin CL. Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer’s disease. Int J Neurosci 2014 (Epub ahead of print).

Wang J, Wang Z. Role of melatonin in Alzheimer-like neurodegeneration. 2006; 27: 41–49.

Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003; 35: 125–130.

Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res 2005; 8: 145–152.

Polimeni G, Esposito E, Bevelacqua V, Guarneri C, Cuzzocrea S. Role of melatonin supplementation in neurodegenerative disorders. Front Biosci (Landmark Ed) 2014; 19: 429–446 .

Wade AG,  Farmer M, Harari G, Fund N,Laudon M,  Nir T, Marom AF,ZisapelN. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging 2014; 9: 947–961.

Wu YH, Feenstra MG, Zhou JN, Liu RY, Torano JS, van Kan HJ. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003; 88: 5898–5906.

Ferrari E, Arcaini A, Gornati R, Pelanconi L, Cravello L. Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. Exp Gerontol 2000; 35: 1239–1250.

Ohashi Y, Okamoto N, Uchida K, Iyo M, Mori N, Morita Y. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer’s type. Biol Psychiatry 1999; 45: 1646–1652.

___

Bibtex @ { tbtkmedical149046, journal = {Turkish Journal of Medical Sciences}, issn = {1300-0144}, eissn = {1303-6165}, address = {}, publisher = {TÜBİTAK}, year = {2015}, volume = {45}, pages = {1073 - 1077}, doi = {}, title = {Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease}, key = {cite}, author = {Şirin, Fevziye Burcu and Doğuç, Duygu Kumbul and Vural, Hüseyin and Eren, İbrahim and İnanlı, İkbal and Sütcü, Recep and Delibaş, Namik} }
APA Şirin, F , Doğuç, D , Vural, H , Eren, İ , İnanlı, İ , Sütcü, R , Delibaş, N . (2015). Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease . Turkish Journal of Medical Sciences , 45 (5) , 1073-1077 .
MLA Şirin, F , Doğuç, D , Vural, H , Eren, İ , İnanlı, İ , Sütcü, R , Delibaş, N . "Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease" . Turkish Journal of Medical Sciences 45 (2015 ): 1073-1077 <
Chicago Şirin, F , Doğuç, D , Vural, H , Eren, İ , İnanlı, İ , Sütcü, R , Delibaş, N . "Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease". Turkish Journal of Medical Sciences 45 (2015 ): 1073-1077
RIS TY - JOUR T1 - Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease AU - Fevziye Burcu Şirin , Duygu Kumbul Doğuç , Hüseyin Vural , İbrahim Eren , İkbal İnanlı , Recep Sütcü , Namik Delibaş Y1 - 2015 PY - 2015 N1 - DO - T2 - Turkish Journal of Medical Sciences JF - Journal JO - JOR SP - 1073 EP - 1077 VL - 45 IS - 5 SN - 1300-0144-1303-6165 M3 - UR - Y2 - 2021 ER -
EndNote %0 Turkish Journal of Medical Sciences Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease %A Fevziye Burcu Şirin , Duygu Kumbul Doğuç , Hüseyin Vural , İbrahim Eren , İkbal İnanlı , Recep Sütcü , Namik Delibaş %T Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease %D 2015 %J Turkish Journal of Medical Sciences %P 1300-0144-1303-6165 %V 45 %N 5 %R %U
ISNAD Şirin, Fevziye Burcu , Doğuç, Duygu Kumbul , Vural, Hüseyin , Eren, İbrahim , İnanlı, İkbal , Sütcü, Recep , Delibaş, Namik . "Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease". Turkish Journal of Medical Sciences 45 / 5 (Aralık 2015): 1073-1077 .
AMA Şirin F , Doğuç D , Vural H , Eren İ , İnanlı İ , Sütcü R , Delibaş N . Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease. Turkish Journal of Medical Sciences. 2015; 45(5): 1073-1077.
Vancouver Şirin F , Doğuç D , Vural H , Eren İ , İnanlı İ , Sütcü R , Delibaş N . Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease. Turkish Journal of Medical Sciences. 2015; 45(5): 1073-1077.
IEEE F. Şirin , D. Doğuç , H. Vural , İ. Eren , İ. İnanlı , R. Sütcü ve N. Delibaş , "Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease", Turkish Journal of Medical Sciences, c. 45, sayı. 5, ss. 1073-1077, Ara. 2015
Turkish Journal of Medical Sciences
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK

52.9b40.5b

Sayıdaki Diğer Makaleler

Association of CLU and TLR2 gene polymorphisms with late-onsetAlzheimer disease in a northwestern Iranian population

Nasim SOHRABIFAR, Jalal GHARESOURAN, Mahnaz TALEBI, Morteza GHOJAZADEH, Seiied Mojtaba Mohaddes ARDEBILI

A Turkish 3-center study evaluation of serum folic acid and vitamin B12 levels in Alzheimer disease

Nuriye Nuray ULUSU, Gökhan YILMAZ, Zübeyde ERBAYRAKTAR, Ahmet Turan EVLİCE, Sevgi ARAS, Görsev YENER, Aslihan AVCI

Neurodegeneration in ocular and central nervous systems: optical coherence tomography study in normal-tension glaucoma and Alzheimer disease*

Muhsin ERASLAN, Eren ÇERMAN, Osman ÇEKİÇ, Sevcan BALCI, Volkan DERİCİOĞLU, Özlem ŞAHİN, Devran SÜER, Biman CHABOU, Emine Neşe Tuncer ELMACI

Is Alzheimer disease related to age-related macular degeneration?

Seden DEMİRCİ, Alime GÜNEŞ, Kadir DEMİRCİ, Serpil DEMİRCİ, Levent TÖK, Özlem TÖK

Role of autophagy in the pathogenesis of Alzheimer disease

MUHAMMET CEMAL KIZILARSLANOĞLU, ZEKERİYA ÜLGER

The reliability and validity of the Turkish version of theNeuropsychiatric Inventory-Clinician

Eylem Şahin CANKURTARAN, Mustafa DANIŞMAN, Hasan TUTAR, Semra Ulusoy KAYMAK

Vitamin D status and its association with gradual decline in cognitive function

YUSUF YEŞİL, MEHMET EMİN KUYUMCU, ÖZGÜR KARA, BURÇİN HALAÇLI, SEZGİN ETGÜL, MUHAMMET CEMAL KIZILARSLANOĞLU, BURCU BALAM YAVUZ, MÜNEVVER ÖZCAN, MELTEM GÜLHAN HALİL, EYLEM ŞAHİN CANKURTARAN, MUSTAFA CANKURTARAN, SERVET ARIOĞUL

Alzheimer disease, inflammation, and novel inflammatory marker: resistin

MUHAMMET CEMAL KIZILARSLANOĞLU, ÖZGÜR KARA, YUSUF YEŞİL, MEHMET EMİN KUYUMCU, ZEYNEL ABİDİN ÖZTÜRK, MUSTAFA CANKURTARAN, SAMED RAHATLI, NAGEHAN PAKAŞTİÇALI, ESAT ÇINAR, MELTEM GÜLHAN HALİL, BURÇİN ŞENER, EYLEM ŞAHİN CANKURTARAN, SERVET ARIOĞUL

Nerve growth factor receptors in dementia

Manoochehr MESSRIPOUR, Abolfazl NAZARIAN, Azadeh MESRIPOUR, İman MOHAMMADI

Prevalence of cognitive impairment and related risk factors incommunity-dwelling elderly in Kayseri, Turkey

Sibel ARGUVANLI, Sibel AKIN, Elif Deniz ŞAFAK, Salime MUCUK, Ahmet ÖZTÜRK, Mustafa Mümtaz MAZICIOĞLU, Hatice Duygu KIZILÇAY, Şemsinnur GÖÇER